1. Scrip

Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine

Clinical Trials Expected To Start In April

 
• By Eleanor Malone

BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.

3D_Coronavirus

German messenger RNA specialist BioNTech SE has signed agreements with Pfizer Inc. and Shanghai Fosun Pharmaceutical Group Co. Ltd. for rights to its investigational COVID-19 vaccine. The mRNA vaccine candidate, BNT162, is expected to enter clinical trials in late April 2020.

Mainz-based BioNTech is building on an existing relationship with Pfizer: the two companies established an R&D collaboration for mRNA flu...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.